Acura Pharmaceuticals (ACUR): Price and Financial Metrics
ACUR Stock Summary
- ACUR has a higher market value than only 1.63% of US stocks; more precisely, its current market capitalization is $6,495,088.
- The capital turnover (annual revenue relative to shareholder's equity) for ACUR is -0.72 -- better than just 5.46% of US stocks.
- Revenue growth over the past 12 months for Acura Pharmaceuticals Inc comes in at 171.47%, a number that bests 96.46% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to Acura Pharmaceuticals Inc are OPGN, ESLT, SPNS, EMAN, and OCFT.
- ACUR's SEC filings can be seen here. And to visit Acura Pharmaceuticals Inc's official web site, go to www.acurapharm.com.
ACUR Stock Price Chart Interactive Chart >
ACUR Price/Volume Stats
| Current price | $0.35 | 52-week high | $0.50 |
| Prev. close | $0.30 | 52-week low | $0.12 |
| Day low | $0.31 | Volume | 3,400 |
| Day high | $0.42 | Avg. volume | 25,654 |
| 50-day MA | $0.27 | Dividend yield | N/A |
| 200-day MA | $0.28 | Market Cap | 7.72M |
Acura Pharmaceuticals (ACUR) Company Bio
Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc.; and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was founded in 1935 and is based in Palatine, Illinois.
Latest ACUR News From Around the Web
Below are the latest news stories about Acura Pharmaceuticals Inc that investors may wish to consider to help them evaluate ACUR as an investment opportunity.
Acura Pharmaceuticals and AD Pharma Amend License to LIMITx™ LTX-03Amendment Extends NDA Acceptance Date and Expands AgreementPALATINE, Ill., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR) today announced an amendment to its License, Development and Commercialization Agreement (“Agreement”) regarding Acura’s LIMITx™ LTX-03 product candidate with Abuse Deterrent Pharmaceuticals, LLC (“AD Pharma”) to extend the FDA Acceptance Date for LTX-03 (“NDA Acceptance Date”), expand the product licenses, and revise the license payment schedule. Acura’s LIMITx™ technology, when applied to any pharmaceutical product, is designed to mitigate the adverse consequences associated with the overdose of tablets. The amended Agreement extends the NDA Acceptance Date to July 31, 2021, expands AD Pharma’s license to the LIMITx™ patents to LTX-02 (... |
Acura Pharmaceuticals Announces First Quarter 2020 Financial ResultsAcura Pharmaceuticals, Inc. (ACUR), a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and product candidates intended to mitigate the risk of outcomes associated with product misuse, announced today financial results for the three months ended March 31, 2020. The Company reported revenues of $1.1 million and an operating loss of $483 thousand for the first quarter 2020 compared to revenues of only $67 thousand and an operating loss of $683 thousand for the same period in 2019. The Company reported a net loss of $595 thousand or $0.02 per diluted share for the first quarter 2020 compared to a net loss of $788 thousand or $0.04 per diluted share for the same period in 2019. |
ACUR Price Returns
| 1-mo | 75.00% |
| 3-mo | 35.50% |
| 6-mo | 25.00% |
| 1-year | 7.73% |
| 3-year | -31.40% |
| 5-year | -83.17% |
| YTD | 66.67% |
| 2020 | -8.70% |
| 2019 | 100.17% |
| 2018 | -71.55% |
| 2017 | -47.55% |
| 2016 | -69.20% |
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Loading social stream, please wait...